Related Experiment Video
Updated: Jan 29, 2026

Laparoscopic Anatomical Liver Segment VII Resection with Liver Parenchymal Transection Following a Priority Approach
Published on: May 23, 2025
The Role of TARE for Bridging and Downstaging of HCC Before Resection or Liver Transplant
Abdullah Alshamrani1, Sung Ki Cho2, Namkee Oh1
1Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 06351, Republic of Korea.
Insights
Transarterial radioembolization (TARE) effectively bridges hepatocellular carcinoma (HCC) patients to curative surgery. This treatment supports favorable long-term survival, with careful patient selection crucial for optimizing outcomes.
Area of Science:
- Hepatology
- Oncology
- Interventional Radiology
Background:
- Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide.
- Locoregional therapies like transarterial radioembolization (TARE) are used to manage HCC.
- TARE aims to downstage tumors and improve eligibility for curative treatments.
Purpose of the Study:
- To evaluate the efficacy of TARE as a bridge to curative surgery in HCC patients.
- To assess the long-term oncological outcomes, including overall survival (OS) and disease-free survival (DFS).
Main Methods:
- Retrospective analysis of 25 HCC patients treated with TARE as neoadjuvant therapy.
- Assessment of TARE's role in facilitating subsequent surgical resection or liver transplantation.
- Evaluation of patient survival data (OS and DFS) via Kaplan-Meier analysis.
Main Results:
- 17 patients underwent surgical resection, and 8 received living-donor liver transplantation (LDLT).
- Median DFS was 11.2 months; median OS for the cohort was 33.4 months.
- 76% of patients were alive and disease-free at last follow-up; LDLT group showed sustained OS.
Conclusions:
- TARE is a viable bridging strategy for selected HCC patients, enabling curative-intent surgery.
- TARE contributes to favorable long-term oncological outcomes and survival benefits.
- Optimizing outcomes requires careful patient selection and multidisciplinary management.
Abstract:
Background: Hepatocellular carcinoma (HCC) remains a major cause of cancer-related mortality. Transarterial radioembolization (TARE) has emerged as a locoregional therapy to downstage tumors and expand surgical eligibility. Methods: This retrospective study included patients with HCC who underwent TARE as a bridging treatment. The primary outcomes assessed were the efficacy of TARE in facilitating curative surgery and long-term oncological outcomes, specifically overall survival (OS) and disease-free survival (DFS). Results: This study included 25 patients. 17 patients subsequently underwent surgical resection and eight underwent living-donor liver transplantation (LDLT). At a median follow-up of 33.4 months, the median disease-free survival (DFS) was 11.2 months. Patients with recurrence had a median DFS of 3.65 months, and those without recurrence had a median DFS of 27.1 months. The median overall survival (OS) for the cohort was 33.4 months. At the last follow-up, 76% of patients were alive and disease-free. Kaplan-Meier analysis demonstrated sustained OS in the LDLT group, while resection patients gradually declined within the first two years. Conclusions: TARE is an effective bridging strategy that enables curative-intent surgery in selected patients with HCC and supports favorable long-term oncological outcomes. Careful patient selection and multidisciplinary management remain essential to optimize survival benefits.
Related Concept Videos
Design Example: Strain Gauge Bridge or Wheatstone Bridge
Wheatstone Bridge
Thus, for accurate resistance measurements, a...
Bridge rectifier
Operationally, the bridge rectifier allows current flow through two of its diodes during each...
Cross-bridge Cycle
Role of Septins
Cellular Functions of Septins
Recent studies have revealed the multifaceted roles of septins in various cellular processes such as cytokinesis, ciliogenesis, and neurogenesis. Septins act as scaffolds and...
The Role of Culture

